CA3129438A1 - Tyk2 pseudokinase ligands - Google Patents

Tyk2 pseudokinase ligands Download PDF

Info

Publication number
CA3129438A1
CA3129438A1 CA3129438A CA3129438A CA3129438A1 CA 3129438 A1 CA3129438 A1 CA 3129438A1 CA 3129438 A CA3129438 A CA 3129438A CA 3129438 A CA3129438 A CA 3129438A CA 3129438 A1 CA3129438 A1 CA 3129438A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
compound
solvate
acceptable salt
c6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129438A
Other languages
English (en)
French (fr)
Inventor
Raju Mohan
John Nuss
Jason Harris
Shendong Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventyx Biosciences Inc
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of CA3129438A1 publication Critical patent/CA3129438A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3129438A 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands Pending CA3129438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
US62/802,642 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
CA3129438A1 true CA3129438A1 (en) 2020-08-13

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129438A Pending CA3129438A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Country Status (12)

Country Link
US (1) US20220135567A1 (https=)
EP (1) EP3920931A4 (https=)
JP (1) JP2022519696A (https=)
KR (1) KR20210124409A (https=)
CN (1) CN113677347A (https=)
AU (1) AU2020218267A1 (https=)
BR (1) BR112021015616A2 (https=)
CA (1) CA3129438A1 (https=)
IL (1) IL285429A (https=)
MX (1) MX2021009555A (https=)
SG (1) SG11202108619SA (https=)
WO (1) WO2020163778A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
EP4214215A1 (en) * 2020-09-16 2023-07-26 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2022156657A1 (en) * 2021-01-19 2022-07-28 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2025061180A1 (zh) * 2023-09-22 2025-03-27 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025165746A1 (en) * 2024-01-30 2025-08-07 Ennovathera, Inc. Certain chemical entities, compositions, and methods
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557110B2 (en) * 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
EP2348860B1 (en) * 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
CN110678467B (zh) * 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
SI3658557T1 (sl) * 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
JP7179161B2 (ja) * 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
AR117177A1 (es) * 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
JP7635228B2 (ja) * 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド

Also Published As

Publication number Publication date
JP2022519696A (ja) 2022-03-24
MX2021009555A (es) 2021-10-13
CN113677347A (zh) 2021-11-19
WO2020163778A1 (en) 2020-08-13
US20220135567A1 (en) 2022-05-05
EP3920931A1 (en) 2021-12-15
IL285429A (en) 2021-09-30
BR112021015616A2 (pt) 2021-11-09
AU2020218267A1 (en) 2021-09-30
KR20210124409A (ko) 2021-10-14
SG11202108619SA (en) 2021-09-29
EP3920931A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
CA3129438A1 (en) Tyk2 pseudokinase ligands
JP7635228B2 (ja) Ｔｙｋ２偽キナーゼリガンド
JP7595582B2 (ja) Ｔｙｋ２偽キナーゼリガンド
KR102916168B1 (ko) Jak 억제제
CA3147571A1 (en) Nlrp3 modulators
AU2020354629A1 (en) JAK inhibitors
CA3150281A1 (en) Jak inhibitors
AU2020267661B2 (en) JAK inhibitors
HK40066192A (zh) Tyk2假激酶配体
HK40066192B (zh) Tyk2假激酶配体
HK40080028B (zh) Tyk2假激酶配体
HK40080028A (en) Tyk2 pseudokinase ligands
HK40064378A (en) Tyk2 pseudokinase ligands

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240205

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250212

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250612

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323